시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 듀센형 근이영양증(DMD) 치료 시장 보고서(2025년)
Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025
상품코드 : 1686114
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,242,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,023,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,803,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 듀셴형 근이영양증(DMD) 치료 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 예측기간의 성장은 듀센형 근이영양증 차료에 대한 투자 증가,의 병행 치료의 채용, 바이오마커의 출현, 듀센형 근이영양증의 스크리닝 프로그램 증가 등에 기인하고 있습니다.

듀센형 근이영양증(DMD) 치료 시장의 성장은 임상시험 증가에 의해 촉진 될 것으로 예상됩니다. 듀센형 근이영양증 치료법에 대한 임상시험의 급증은 연구, 기술 혁신, 다양한 치료의 가능성에 대한 지속적인 헌신을 강조하는 것입니다. National Institutes of Health(NIH)의 한 부문인 Clinicaltrials.gov가 2023년 8월에 보고한 바에 따르면, 등록된 임상시험의 수는 464,218건으로 2021년의 399,496건에서 크게 증가하고 있습니다. 게다가, 이러한 시험의 31%(총 142,700건)는 미국 내에서 등록되었으며, 나머지 53%(248,310건)는 국제적인 장소에서 기록되고 있습니다.

유전성 질환의 유병률의 상승은 향후 듀센형 근이영양증(DMD) 시장의 성장을 이끌 것으로 예상됩니다. 유전성 질환의 발생이 증가함에 따라, 유전자 변이나 가족력에 의해 DMD를 발병할 위험이 있는 인구가 증가할 가능성이 있으며, DMD 관련 진단, 치료, 처치에 대한 수요가 높아집니다. 2022년 2월, 스위스에 본부를 둔 정부간 기관인 세계보건기구(WHO)는 출생시의 이상으로 매년 생후 28일 이내에 24만명의 신생아가 사망하고 있다고 보고했습니다. 게다가, 1개월부터 5세까지의 17만명의 아이가, 심장 이상, 신경관 폐쇄 장애, 다운증 등의 출생시 이상이 원인으로 사망하고 있습니다. 그 결과, 유전성 질환의 유병률 증가가 DMD 시장의 확대를 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Duchenne muscular dystrophy (DMD) therapeutics encompass a range of medical interventions and treatments devised to address and mitigate the symptoms associated with DMD, a genetic ailment characterized by progressive muscle weakening and deterioration. The primary objective of these therapeutic strategies is to retard the advancement of the disease, enhance muscle function, and augment the overall well-being of individuals afflicted by Duchenne muscular dystrophy.

The principal categories of DMD therapeutics consist of small molecules and biologics. Small molecules are compounds with low molecular weight that can specifically interact with certain proteins or targets within the body. These can be tailored to address various facets of DMD, such as mitigating inflammation, fostering muscle regeneration, or targeting specific genetic mutations. The distribution of these therapeutics occurs through both offline and online channels, catering to applications in hospitals, clinics, and home care settings.

The duchenne muscular dystrophy (DMD) therapeutics market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy (DMD) therapeutics market statistics, including duchenne muscular dystrophy (DMD) therapeutics industry global market size, regional shares, competitors with a duchenne muscular dystrophy (DMD) therapeutics market share, detailed duchenne muscular dystrophy (DMD) therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the duchenne muscular dystrophy (DMD) therapeutics industry. This duchenne muscular dystrophy (DMD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy (DMD) therapeutics market size has grown exponentially in recent years. It will grow from $11.95 billion in 2024 to $16.45 billion in 2025 at a compound annual growth rate (CAGR) of 37.6%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives.

The duchenne muscular dystrophy (DMD) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $47.34 billion in 2029 at a compound annual growth rate (CAGR) of 30.3%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments.

The growth of the Duchenne muscular dystrophy (DMD) therapeutics market is anticipated to be propelled by the increasing number of clinical trials. Clinical trials represent essential research studies involving human participants aimed at assessing the safety, efficacy, and potential advantages of new medical treatments, interventions, or medications. The upsurge in clinical trials dedicated to exploring Duchenne muscular dystrophy treatments underscores the ongoing commitment to research, innovation, and a diverse range of therapeutic possibilities. This trend is poised to result in improved patient outcomes, heightened investments, and the accelerated development and accessibility of effective DMD therapies. For example, in August 2023, as reported by Clinicaltrials.gov, a branch of the National Institutes of Health (NIH), the number of registered clinical trials has increased to 464,218, marking a significant rise from 399,496 in 2021. These trials are conducted across all 50 states of the United States and in 221 countries. Additionally, 31% of these studies, totaling 142,700, are registered within the U.S., while the remaining 53% of studies (248,310) are documented in international locations. Consequently, the escalating count of clinical trials is expected to be a driving force behind the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.

The rising prevalence of genetic disorders is expected to drive the growth of the Duchenne muscular dystrophy (DMD) market in the future. Genetic disorders are conditions caused by abnormalities or mutations in an individual's DNA or genetic material. As the occurrence of genetic disorders increases, a larger population may be at risk of developing DMD due to genetic mutations or family history, leading to greater demand for DMD-related diagnostics, treatments, and therapies. For example, in February 2022, the World Health Organization (WHO), a Switzerland-based intergovernmental body, reported that birth abnormalities cause 240,000 newborn deaths within the first 28 days of life each year. Furthermore, an additional 170,000 children aged 1 month to 5 years die due to birth abnormalities, such as heart defects, neural tube defects, and Down syndrome. As a result, the growing prevalence of genetic disorders is driving the expansion of the DMD market.

The leading companies in the field of Duchenne muscular dystrophy (DMD) therapeutics are embracing innovative technologies to enhance the effectiveness and accessibility of treatments for DMD patients while maintaining their competitive edge in the market. A case in point is Bit Bio Ltd., a UK-based synthetic biology company, which, in July 2023, introduced disease model products aimed at advancing Duchenne muscular dystrophy (DMD) treatments. These disease models, specifically the ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, consist of human skeletal myocytes engineered to carry deletions in the gene responsible for dystrophin protein production. Derived from induced pluripotent stem cells (iPSCs), Bit Bio's models offer a reliable and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. These models provide valuable insights into disease mechanisms and potential therapies, supporting the development of treatments for DMD. This technological advancement has the potential to expedite the work of researchers striving to find effective solutions for Duchenne muscular dystrophy.

In December 2022, Solid Biosciences Inc., a biotechnology firm headquartered in the United States, successfully completed the acquisition of AavantiBio, Inc. The financial details of the transaction remain undisclosed. This acquisition represents a significant move by Solid Biosciences to extend its collection of gene therapy programs, focusing on neuromuscular and cardiac diseases. The incorporation of AavantiBio, Inc. has not only broadened the company's capabilities but also brought in valuable expertise and financial resources for advancing research and development efforts and reaching potential milestones. AavantiBio, Inc., a gene therapy company based in the United States, specializes in the development of groundbreaking treatments for Duchenne muscular dystrophy and various other neuromuscular and cardiac diseases.

Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.

North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the duchenne muscular dystrophy (DMD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on duchenne muscular dystrophy (dmd) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for duchenne muscular dystrophy (dmd) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy (dmd) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Characteristics

3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies

4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Analysis And Strategic Analysis Framework

6. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

7. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market

9. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market

10. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market

11. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market

12. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

13. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

14. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market

15. Western Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

16. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market

17. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market

18. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market

19. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market

20. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Market

21. Eastern Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market

22. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market

23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

24. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Market

25. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market

26. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market

27. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market

28. Middle East Duchenne Muscular Dystrophy (DMD) Therapeutics Market

29. Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market

30. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Landscape And Company Profiles

31. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Other Major And Innovative Companies

32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

34. Recent Developments In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market

35. Duchenne Muscular Dystrophy (DMD) Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기